VTGN — Vistagen Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $64.07m
- -$24.49m
- $1.06m
Annual cashflow statement for Vistagen Therapeutics, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -20.8 | -17.9 | -47.8 | -59.2 | -29.4 |
| Depreciation | |||||
| Non-Cash Items | 4.75 | 2.31 | 3.71 | 3.41 | 2.19 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.175 | 3.08 | -1.92 | 5.59 | 0.793 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -15.8 | -12.1 | -45.3 | -49.7 | -25.8 |
| Capital Expenditures | 0 | -0.275 | -0.2 | -0.212 | -0.061 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | -0.528 | 0 |
| Acquisition of Business | |||||
| Cash from Investing Activities | 0 | -0.275 | -0.2 | -0.74 | -0.061 |
| Financing Cash Flow Items | — | — | 4.04 | -0.174 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.01 | 114 | 10.5 | -1.04 | 128 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -11.7 | 102 | -35 | -51.5 | 103 |